Home  »  Business   »  What Do Analysts Think Of NeuroSense Therapeutics ...

What Do Analysts Think Of NeuroSense Therapeutics Ltd. (NRSN)

NeuroSense Therapeutics Ltd. (NRSN) saw an uptrend of 7.45% in the recent trading with $2.02 being its most recent. The current price level -75.31% lower than the highest price of $8.18 marked by the stock while trading over the past 52-weeks, whereas it is 64.23% higher than the lowest price of $1.23 the company dropped to over past 52-weeks. The latest news story on NRSN appeared in PR Newswire under the title “NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study” on Aug-02-22.

Squeezing the time span to 30 day period shows us the stock is currently trading -38.41% below one month high and is +15.43% above of the lowest during that time. Looking into the simple moving average, NeuroSense Therapeutics Ltd. (NRSN)’s stock stands at a SMA-50 of $1.9400 while that of 5-day is reading $1.9100.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Do analysts rate it as a buy, sell or hold?

Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Moderate Buy by 1 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.00 for the stock.

NeuroSense Therapeutics Ltd. Earnings – What Happened With NRSN

Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.

NRSN – NeuroSense Therapeutics Ltd. Stock Earnings Estimates

Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 10.99 million. NRSN does have institutional investors; and they hold 1.40% of the stock.

NeuroSense Therapeutics Ltd. – Insider Activity and Holdings

Currently, the stock has been recommended as Moderate Buy by 1 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.00 for the stock.

The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by NeuroSense Therapeutics Ltd. was 19.12 while posting a debt to equity ratio of 0.02.

Technical Analysis of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) stock

Leave a Comment

Your email address will not be published.

More Posts

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free
384869

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.